MedPage Today October 21, 2021
— NIH experts: Rapid response to COVID-19 has “silver lining” for tough-to-treat diseases
There’s no denying that the pandemic led to disruptions for research in rare diseases, but the public health crisis did have a “silver lining” for this patient population, NIH investigators said.
“COVID-19 came along and it was a little distracting,” conceded Matt Hall, PhD, director of the NIH National Center for Advancing Translational Sciences (NCATS) Early Translation Branch, speaking at the NORD Rare Disease and Orphan Products Breakthrough Summit on Tuesday.
Many labs weren’t able to run at full capacity, and some still aren’t, he explained during the town hall. Yes, NCATS scientists had to set aside non-COVID-19 research “for a short period of time,” he noted.
...Today's Sponsors
Today's Sponsor